Virtual Journal Club

Please note: This website is for discussion purposes only. The information provided at this website is not intended to provide treatment advice, or to diagnose or treat any medical disorder. The creator of this website is not responsible for events that occur as a result of decisions made based on the information presented here.

Citations powered by PubMed

C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort.

October 7th, 2009 · Start a Discussion

Related Articles

C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort.

Thromb Haemost. 2009 Oct;102(4):615-9

Authors: Folsom AR, Lutsey PL, Astor BC, Cushman M

The role of inflammation in the causation of venous thromboembolism (VTE) is uncertain. In 10,505 participants of the Atherosclerosis Risk in Communities (ARIC) Study, we assessed the association of the systemic inflammation marker, elevated C-reactive protein (CRP), with incidence of VTE (n=221) over a median of 8.3 years of follow-up. Adjusted for age, race, and sex, the hazard ratios of VTE across quintiles of CRP were 1.0, 1.61, 1.16, 1.56, and 2.31 (p for trend p<0.0007). For CRP above the upper 10 percentile (>/=8.55 mg/L), compared with the lowest 90% of CRP values, the hazard ratio of VTE was 2.07 (95% CI 1.47, 2.94). Further adjustment for baseline hormone replacement therapy, diabetes, and body mass index attenuated the hazard ratios only slightly. For example, the adjusted hazard ratio of VTE was 1.76 (95% CI 1.23, 2.52) for CRP above versus below the 90(th) percentile. In conclusion, this prospective, population-based study suggests elevated CRP is independently associated with increased risk of VTE.

PMID: 19806245 [PubMed - in process]

Link to Abstract at PubMed

Share


Tags: Thromb Haemost

0 responses so far ↓

  • There are no comments yet...Kick things off by filling out the form below.

Discuss this article